0
Sign In  | Subscribe
5 August 2003, Vol 139, No. 3>
Summaries for Patients | 5 August 2003

Oral Administration of an Antibiotic (Norfloxacin) May Help Treat the Cardiac and Circulatory Complications of Liver Failure FREE

Ann Intern Med. 2003;139(3):I-62. doi:10.7326/0003-4819-139-3-200308050-00004
Text Size: A A A

What is the problem and what is known about it so far?

Advanced liver failure affects many organs in addition to the liver. For example, when the liver fails, the circulatory system reacts by relaxing the muscular coating that surrounds blood vessels. This allows blood vessels to open wider, causing blood to flow more rapidly through the vessels. As a result, to maintain blood pressure at safe levels, the heart must beat faster and the amount of blood pumped by the heart (the cardiac output) must increase. This altered condition of the circulatory system, known as a “hyperdynamic circulatory state,” puts a dangerous strain on the heart and may cause death. Certain types of bacteria cause this problem when they invade the bloodstream. Doctors have speculated that the circulatory changes that accompany liver failure occur because the liver, which normally removes bacteria that leak into the bloodstream from the bowel, can no longer perform this function. Until now, no effective treatment has been available for the hyperdynamic circulatory state that accompanies liver failure.

Why did the researchers do this particular study?

To find out whether oral administration of norfloxacin (an antibiotic that kills bacteria in the bowel) could block the effects of liver failure on the circulatory system.

Who was studied?

14 men with alcohol-related liver disease (cirrhosis) who were compared to 14 healthy male volunteers of the same age.

How was the study done?

Participants with cirrhosis were randomly assigned to receive either norfloxacin capsules or placebo capsules (that looked exactly like norfloxacin) for 28 days. Neither the patient nor the doctor knew which capsule was being taken. After 28 days of treatment, the capsules were switched; the participants who had taken norfloxacin were given placebo and those who had taken placebo were given norfloxacin for another 28 days. At the end of each treatment period, a blood sample was drawn in participants with cirrhosis to test for the presence of bacterial products in the bloodstream (endotoxins) and for the level of natural chemicals that maintain blood pressure. In addition, the researchers measured cardiac output and kidney function. Normal volunteers underwent studies only once and received no medication.

What did the researchers find?

Measurements in normal participants were compared with the results in cirrhotic participants who took norfloxacin or placebo. When cirrhotic persons took norfloxacin capsules, blood pressure improved, blood flow through the vessels became more normal, and cardiac output decreased slightly (but not significantly). Norfloxacin had no effect on how well the kidneys were working.

What were the limitations of the study?

The researchers could not confirm the exact way that norfloxacin caused the circulatory changes that they observed. Additional factors must be involved in producing the hyperdynamic circulatory state because norfloxacin did not completely block its manifestations.

What are the implications of the study?

Oral administration of norfloxacin may be helpful in treating a dangerous side effect of liver failure.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general jounals
BMJ 2010;341:c5893-c1494.

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy This Article

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Advertisement

Related Content

Customize your page view by dragging & repositioning the boxes below.

Topic Collections
PubMed Articles
Therapeutic strategies and emergence of multiresistant bacterial strains.
Internal and emergency medicine Issue date: 2010 Oct
Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.
Gastroenterology Issue date: 2006 Oct

Annals of Internal Medicine

Other Resources

Copyright © 2013 The American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Buy This Article

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)